GlassScriptPhysician profile
Michael Dohrenwend
NPI 1922089598
$8,686.71
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,490 · 2020: $1,182 · 2021: $1,069 · 2022: $945.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,384.37 | 2019-2022 | |
| Abbvie INC. | $1,002.44 | 2019-2022 | |
| Gilead Sciences, INC. | $510.01 | 2019-2022 | |
| Braintree Laboratories, INC. | $400.41 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $324.53 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $219.87 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.85 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $112.38 | 2020-2022 | |
| Redhill Biopharma INC. | $95.79 | 2020-2022 | |
| Janssen Biotech, INC. | $90.35 | 2019-2022 | |
| Allergan, INC. | $61.67 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.12 | 2020-2021 | |
| Ethicon US, LLC | $52.05 | 2019-2021 | |
| Qol Medical, LLC | $47.84 | 2021 | |
| Ardelyx, INC. | $36.02 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $34.58 | 2022 | |
| Pentax of America, INC. | $29.50 | 2022 | |
| Genzyme Corporation | $19.53 | 2022 | |
| Daiichi Sankyo INC. | $18.68 | 2021 | |
| Medtronic, INC. | $18.46 | 2021 | |
| Alfasigma USA, INC. | $17.09 | 2020 | |
| Zyla Life Sciences, INC. | $13.31 | 2020 | |
| Pfizer INC. | $12.86 | 2022 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dohrenwend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.